{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-164027","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.879177+00:00","generated_at":"2026-06-14T03:56:57.564035+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Amylyx shareholders elect two Class II directors and ratify Deloitte as auditor","bullets":["George Mclean Milne Jr. and Paul Fonteyne elected as Class II directors; term until 2026.","Milne received 44,362,315 votes for, 9,410,140 withheld; Fonteyne 44,736,816 for, 9,035,639 withheld.","Ratification of Deloitte & Touche as independent auditor for FY 2023 passed with 57,585,098 votes for.","No other matters were submitted to or voted on at the annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-164027","json":"https://secwatch.observer/filing/0001193125-23-164027.json","markdown":"https://secwatch.observer/filing/0001193125-23-164027.md","text":"https://secwatch.observer/filing/0001193125-23-164027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312523164027/0001193125-23-164027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312523164027/d501159d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:56:57.564035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc2f1fa0efbae8cf6e8e46a88f457d08afe1a780","claim":"Amylyx Pharmaceuticals, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-08 meeting.","evidence_excerpt":"The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312523164027/0001193125-23-164027-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"f2271ee58e6bdc6d1f62867167c478c9371597ad","claim":"Amylyx Pharmaceuticals, Inc. shareholders approved Election of Class II Directors at the 2023-06-08 meeting.","evidence_excerpt":"The stockholders of the Company elected George Mclean Milne Jr., Ph.D. and Paul Fonteyne as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2026 or until their successors have been duly elected and qualified or until their earlier resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312523164027/0001193125-23-164027-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}